lifestyle.celebhomes.net
Home
Sample Page
Author:
Propanc Biopharma, Inc.
Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
May 13, 2026
Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain
March 24, 2026
Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy
March 12, 2026
Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study
March 10, 2026
Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market
February 6, 2026
Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations
January 27, 2026
Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia
January 20, 2026